Document is current

Article History

Received: 28 June 2016

Accepted: 7 March 2018

First Online: 15 March 2018

Authors’ information

: Susen Burock: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany.Severin Daum: Department of Medicine I, Gastroenterology, Rheumatology and Infectious Diseases, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.Ulrich Keilholz: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.Konrad Neumann: Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany, Department for Biostatistics and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.Wolfgang Walter: Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany.Ulrike Stein: Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

: The final protocol was approved by the ethics committee of the Landesamt für Gesundheit und Soziales (LAGeSo), Berlin, Germany and the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and is registered at EudraCT database (EudraCT 2014-005151-20) and at Clinicaltrials.gov (NCT02519582).This study complies with the Declaration of Helsinki in its recent version, the Medical Association’s professional code of conduct, the principles of the International Conference on Harmonisation about Good Clinical Practice guidelines (ICH-GCP) and the Federal Data Protection Act. The trial will also be carried out in keeping with local legal and regulatory requirements. The medical secrecy and the Federal Data Protection Act will be followed.Written informed consent is obtained from each patient in oral and written form before inclusion in the trial and the nature, scope, and possible consequences of the trial have been explained by a physician. The investigator will not undertake any measures specifically required only for the clinical trial until valid consent has been obtained.

: The authors declare that they have no competing interests, besides the following patent applications:Stein U, Walther W, Sack U, Scudiero D, Schlag PM, Shoemaker RH. Niclosamide for treatment of cancer metastasis. US 14/112,521(12.11.2013), EP2012/057049 (18.4.2012).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.